ChemicalBook > Product Catalog >API >Antineoplastic agents >Natural sources of antineoplastic >Paclitaxel

Paclitaxel

Paclitaxel is a monomer diterpenoid compound extracted from bark of the natural plant, taxus. It is a kind of complex secondary metabolites and is currently known as the only kind drug that can promote microtubule polymerization and stabilize polymerized microtubules. Isotopic tracing has showed that paclitaxel only binds to polymerized microtubules without reacting with the non-polymerized tubulin dimer.
Paclitaxel Suppliers list
Company Name: Jiangsu Yew Pharmaceutical Co., Ltd.
Tel: +86-510-66865338 +86-189-2133-5032 jiangwenjun@hongdou.com
Email: junwenjiang@live.cn , jiangwenjun@hongdou.com
Products Intro: Product Name:paclitaxel
CAS:33069-62-4
Purity:99% Package:1KG;31750USD
Company Name: Beijing Yibai Biotechnology Co., Ltd
Tel: 0086-182-6772-3597
Email: sales01@yibaibiotech.com
Products Intro: Product Name:Paclitaxel
CAS:33069-62-4
Purity:99% Package:1g;USD|10g;USD|100g;USD|1KG;USD
Company Name: Frapp's ChemicalNFTZ Co., Ltd.
Tel: +86 (576) 8169-6106
Email: sales@frappschem.com
Products Intro: Product Name:Paclitaxel
CAS:33069-62-4
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: Product Name:33069-62-4
CAS:33069-62-4
Purity:0.99 Package:25KG,5KG;1KG;500G
Company Name: PI & PI BIOTECH INC.
Tel: 020-81716320
Email: Sales@pipitech.com
Products Intro: Product Name:Paclitaxel
CAS:33069-62-4
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Sales@pipitech.com Remarks:5β,20-Epoxy-1,7β-dihydroxy-9-oxotax-11-ene-2α,4,10β,13α-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate].

Lastest Price from Paclitaxel manufacturers

  • Paclitaxel 33069-62-4
  • US $15.00 / mg
  • 2020-02-10
  • CAS:33069-62-4
  • Min. Order: 20mg
  • Purity: ≥98%
  • Supply Ability: 1000.00 kgs
  • Paclitaxel
  • US $2.00 / KG
  • 2020-01-16
  • CAS: 33069-62-4
  • Min. Order: 1KG
  • Purity: 98%
  • Supply Ability: 500 Ton/Tons per Month
  • Paclitaxel
  • US $10.00 / KG
  • 2019-12-02
  • CAS:33069-62-4
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 10 mt

Related articles

Paclitaxel Basic information
Indications and Usage Mechanisms of Action Warnings and Precautions
Product Name:Paclitaxel
Synonyms:Docetaxel EP impurity F paclitaxel;-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4;12a-alpha,12b-alpha))-12-alpha;4,10-diacetate2-benzoate13-esterwith(2r,3s)-n-benzoyl-3-phenylisoserine;5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one;-9-ylester;a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca(3,4)benz(1,2-b)oxet-9-y;benzenepropanoicacid,beta-(benzoylamino)-alpha-hydroxy-,6,12b-bis(acetyloxy)
CAS:33069-62-4
MF:C47H51NO14
MW:853.91
EINECS:608-826-9
Product Categories:Active Pharmaceutical Ingredients;Pharmaceutical material and intermeidates;Antineoplastics;Plant extract;API;Plant extracts;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;CLOBEX;Isolabel;antibiotic;Inhibitors;Antineoplastic;APIs;Antitumors for Research and Experimental Use;Biochemistry;Natural Plant Extract;Intermediates & Fine Chemicals;Pharmaceuticals;Natural Anti-cancer Medical Materials and It's Derivatives;Antitumour;Signalling;Aromatics;Chiral Reagents;Heterocycles;Anti-cancer&immunity
Mol File:33069-62-4.mol
Paclitaxel Structure
Paclitaxel Chemical Properties
Melting point 213 °C (dec.)(lit.)
alpha D20 -49° (methanol)
Boiling point 774.66°C (rough estimate)
density 0.200
refractive index -49 ° (C=1, MeOH)
Fp 9℃
storage temp. 2-8°C
solubility methanol: 50 mg/mL, clear, colorless
form powder
pka11.90±0.20(Predicted)
color white
Water Solubility 0.3mg/L(37 ºC)
λmax227nm(MeOH)(lit.)
Merck 14,6982
BRN 1420457
Stability:Stable. Incompatible with strong oxidizing agents. Combustible.
InChIKeyRCINICONZNJXQF-MZXODVADSA-N
CAS DataBase Reference33069-62-4(CAS DataBase Reference)
EPA Substance Registry SystemPaclitaxel (33069-62-4)
Safety Information
Hazard Codes Xn
Risk Statements 37/38-41-42/43-62-68-40-48-20/21/22-68/20/21/22
Safety Statements 22-26-36/37/39-45
RIDADR 1544
WGK Germany 3
RTECS DA8340700
10-21
HazardClass 6.1(b)
PackingGroup III
HS Code 29329990
Hazardous Substances Data33069-62-4(Hazardous Substances Data)
ToxicityLD50 intraperitoneal in mouse: 128mg/kg
MSDS Information
ProviderLanguage
Paclitaxel English
ACROS English
SigmaAldrich English
Paclitaxel Usage And Synthesis
Indications and UsagePaclitaxel is a monomeric diterpene compound extracted from Chinese yew bark and is a complicated secondary metabolite. Stage II-III clinical studies show that paclitaxel is most suitable for ovarian and breast cancer, and has certain efficacy in treating prostate cancer, lung cancer, colorectal cancer, melanoma, head and neck cancer, esophageal cancer, germ cell tumors, endometrial cancer, lymphoma, brain tumors, bladder cancer, upper gastrointestinal cancer, small cell and non-small cell lung cancer.
Mechanisms of ActionPaclitaxel is currently the only known drug that can promote microtubule polymerization and stabilize polymerized microtubules. It can only form on polymerized microtubules and does not react with non-polymerized microtubule protein dipolymers. After coming in contact with paclitaxel, cells will accumulate a large number of microtubules within themselves, which disrupts cell functions, especially cell division, which is forced to cease at the mitotic stage.
Warnings and Precautions1. Hermatological toxicity: the main factor in increased dosage limitations; when white blood cells are below 1500/mm3, supplement with G-CSF; when platelets are below 30000/mm3, transfuse component blood.
2. Allergic reaction: Aside from preconditions, if there are only minor symptoms such as flushed face, skin reactions, slightly increase heart rate, slightly lowered blood pressure, etc., do not stop treatment and decrease injection speed. If there are serious reactions such as hypotension, vascular edema, difficulty breathing, measles, etc., stop treatment and treat accordingly. Patients with serious allergic reactions should not use paclitaxel in the future.
3. Nervous system: Common reactions include numb toes. Approximately 4% patients, especially with high dosage, experience significant sensory and motor difficulty and decreased tendon reflex. There have been individual reports of epilepsy.
4. Cardiovascular: Transient tachycardia and hypotension are common and do not usually require attention. However, monitor closely during first hour of injection. Afterwards, only patients with serious injection difficulty require hourly check-ins.
5. Join and muscle: Approximately half of the patients will experience some joint and muscle pain within the first 2-3 days following injection, which is related to dosage, and usually subsides after a couple days. Patients who are also administered G-CSF will experience heightened muscle pain.
6. Liver and gall: As paclitaxel is mainly excreted through bile, patients with liver and gall diseases must be monitored carefully. Among thousands of cases, 8% of patients experienced increased bilirubin, 23% experienced increased alkaline phosphatase, and 18% experienced increased glutamic-oxalacetic transaminase. However, there is currently no evidence indicating that paclitaxel causes any severe liver damage.
7. Other: Digestive tract reactions are common but rarely severe, with few cases of diarrhea and mucosa infection. Slight alopecia is also common.
DescriptionPaclitaxel, a natural product isolated from the bark of the Pacific yew, is effective in treating refractory metastatic ovarian cancer. Unlike any other antineoplastic agents, paclitaxel appears to have several possible mechanisms of action, including an antimicrotubule action through the promotion of tubulin polymerization and stabilization of microtubules, thereby, halting mitosis and promoting cell death. The supply of paclitaxel is limited by its low natural abundance and currently it is being manufactured by a semi-synthetic route from deacetylbaccatin Ⅲ that is isolated from the needles of the yew tree. Recent completion of two total syntheses of taxol conquered the structural complexity of the title compound and may be useful in obtaining certain closely related analogs, some of which have been found to have antitumor activity. Paclitaxel has potential uses in the treatment of metastatic breast cancer, lung cancer, head and neck cancer, and malignant melanoma.
Chemical PropertiesWhite Powder
OriginatorNIH (U.S.A.)
Usesglucocorticoid, antiinflammatory
UsesAn antineoplastic. Used in the study of structure and function of microtubles into tubulin. Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanc ed forms of Kaposi's sarcoma. Paclitaxel is a mitotic inhibitor used in cancer chemotherapy.
UsesTool in study of structure and function of microtubules.
IndicationsPaclitaxel (Taxol) is a highly complex, organic compound isolated from the bark of the Pacific yew tree. It binds to tubulin dimers and microtubulin filaments, promoting the assembly of filaments and preventing their depolymerization. This increase in the stability of microfilaments results in disruption of mitosis and cytotoxicity and disrupts other normal microtubular functions, such as axonal transport in nerve fibers. The major mechanism of resistance that has been identified for paclitaxel is transport out of tumor cells, which leads to decreased intracellular drug accumulation. This form of resistance is mediated by the multidrug transporter P-glycoprotein.
Brand nameAbraxane (Abraxis); Taxol (Bristol-Myers Squibb).
General DescriptionNeedles (from aqueous methanol) or fine white powder. An anti-cancer drug.
General DescriptionPaclitaxel is available in single-dose vials of 30 mg/5 mLand 100 mg/16.7 mL for IV administration in the treatmentof breast, ovarian, NSCLC, and AIDS-related Kaposi sarcoma.Other uses have included treatment of head, neck,esophageal, cervical, prostate, and bladder cancers.
Paclitaxel is highly plasma protein bound (>90%) anddoes not penetrate the CNS. Metabolism involves CYPmediatedoxidation to give 6 -hydroxypaclitaxel (CYP2C8)and para hydroxylation of the phenyl group attached to the3'-position (CYP3A4). The 6α-hydroxy metabolite normallypredominates, but the para hydroxy metabolite mayoccur to a greater degree in those patients with liver diseaseor when CYP3A4 has been induced. Both metabolites areless active than the parent and do not undergo phase II conjugationreactions. Elimination occurs primarily in the feces,and the elimination half-life is 9 to 50 hours depending onthe infusion period.
The major toxicity seen with paclitaxel is a dose-limitingmyelosuppression that normally presents as neutropenia. Thepreviously mentioned hypersensitivity reactions occur but aregreatly reduced by antihistamine pretreatment. Interactionwith the axonal microtubules such as that seen for the vincasalso occurs and leads to numbness and paresthesias (abnormaltouch sensations including burning and prickling). Theagent is also available as an albumin-bound formulation(Abraxane) to eliminate the need for the solubilizing agentsassociated with the hypersensitivity reactions. Other adverseeffects include bradycardia, which may progress to heartblock, alopecia, mucositis, and/or diarrhea. Paclitaxel producesmoderate nausea and vomiting that is short-lived.
Air & Water ReactionsMay be sensitive to prolonged exposure to moisture. .
Health HazardTOXIC; inhalation, ingestion or skin contact with material may cause severe injury or death. Contact with molten substance may cause severe burns to skin and eyes. Avoid any skin contact. Effects of contact or inhalation may be delayed. Fire may produce irritating, corrosive and/or toxic gases. Runoff from fire control or dilution water may be corrosive and/or toxic and cause pollution.
Fire HazardFlash point data for Paclitaxel are not available. Paclitaxel is probably combustible.
Biological ActivityAntitumor agent; promotes and stabilizes tubulin polymerization, causing cell cycle arrest. Induces autocatalytic activation of caspase-10 in CCRF-HSB-2 cells, triggering apoptosis.
Mechanism of actionPaclitaxel’s large volume of distribution indicates significant tissue binding. The drug is extensively metabolized by the liver, and doses must be reduced in patients with abnormal liver function or with extensive liver metastases.Very little of the drug is excreted in the urine.
Clinical UsePaclitaxel is among the most active of all anticancer drugs, with significant efficacy against carcinomas of the breast, ovary, lung, head, and neck. It is combined with cisplatin in the therapy of ovarian and lung carcinomas and with doxorubicin in treating breast cancer.
Anticancer ResearchIt is isolated from the bark of Taxus brevifolia generally known as pacific yew. It isprimarily used in ovarian, small, and non-small cell lung cancers and advancedbreast cancer (Shoeb 2006). It binds to tubulin but neither depolymerizes it nor interferes with its assembly (Balunas and Kinghorn 2005). Taxol targets activatorprotein 1 signaling pathways (Singh et al. 2016b).
Anticancer ResearchPaclitaxel (commercial name, Taxol) a complex diterpene alkaloid isnaturally obtained from Taxus species (family Taxaceae). Paclitaxel has been provedas highly effective in the treatment of various types of cancers, since it acts as amicrotubule-stabilizing agent to protect against disassembly. Paclitaxel was developed by the National Cancer Institute, USA, as a drug for cancer therapy andused for the treatment of refractory ovarian cancer, metastatic breast and lung cancer,and Kaposi’s sarcoma (Srivastava et al. 2005). The natural source of paclitaxelis the bark of several Taxus species; however, the cost of extraction is very highsince the concentration of paclitaxel accumulation is very low (0.02% of dry weight)and also entails the destruction of natural resources (Cusido et al. 2014). Eventhough, paclitaxel can be chemically synthesized, but this process is not commerciallyviable. Plant cell cultures have been developed for the production of paclitaxelby Phyton Biotech in 1995, and in 2004 the FDA has approved the use of plantculture supply of paclitaxel/Taxol (Leone and Roberts 2013).
Side effectsMyelosuppression is the major side effect of paclitaxel. Alopecia is common, as is reversible dose-related peripheral neuropathy. Most patients have mild numbness and tingling of the fingers and toes beginning a few days after treatment. Mild muscle and joint aching also may begin 2 or 3 days after initiation of therapy. Nausea is usually mild or absent. Severe hypersensitivity reactions may occur. Cardiovascular side effects, consisting of mild hypotension and bradycardia, have been noted in up to 25% of patients.
Paclitaxel Preparation Products And Raw materials
Raw materialsEthyl acetate-->Silica gel-->Celite
Tag:Paclitaxel(33069-62-4) Related Product Information
Irinotecan Irinotecan hydrochloride polyglutamic acid-paclitaxel PACLITAXEL SOLUTION STD 0.5mg/mL(P) paclitaxel-transferrin (-)-Paclitaxel-2''-hemisuccinate 6a-Hydroxy Paclitaxel-d5 SIDE CHAINS OF PACLITAXEL--3 poly(ethylene glycol)-conjugated paclitaxel-2'-glycinate XYLOSYLTAXOL PACLITAXEL-[BENZOATE RING-UL-14C] 7-(2',3''-DIHYDROXYPROPYL CARBONOXY)PACLITAXEL 6a-Hydroxy Paclitaxel PACLITAXEL C13 LABELED PACLITAXEL, [2-BENZOYL RING-14C(U)] PACLITAXEL-D5 3'-P-HYDROXYTAXOL XYLOSYLTAXOL, 7